Reed NewsReed News
Health1 min

Swedish agency rejects subsidy for obesity drug Wegovy

Key Points
  • The Swedish Dental and Pharmaceutical Benefits Agency (TLV) has rejected a subsidy for the obesity drug Wegovy.
  • The decision was announced by the manufacturer Novo Nordisk in a press release.
  • Multiple Swedish news sources reported the development, but details on the reasons or timing are not provided.

The Swedish Dental and Pharmaceutical Benefits Agency (TLV) has said no to a subsidy for the obesity drug Wegovy, according to reports from multiple Swedish newspapers. The manufacturer Novo Nordisk announced this in a press release. The decision was reported by sources including Smålandsposten, Borås Tidning, Barometern-OT, BLT Blekinge Läns Tidning, Kristianstadsbladet, Vestmanlands Läns Tidning, Sundsvalls Tidning, Nerikes Allehanda, Helsingborgs Dagblad, and Skånska Dagbladet.

The reports do not specify the reasons for the rejection or provide further details on the timing or implications of the decision.

Transparency

How we verified this article

HighBased on 14 sources
14 sources3 Involved